Indeed, a direct causal link between inflammation and cancer was demonstrated by a large clinical study, the CANTOS trial, where treatment with a monoclonal antibody targeting IL-1β (canakinumab) not only significantly reduced the incidence of recurrent cardiovascular events in the absence of lipid lowering in patients with myocardial infarction compared with placebo, but also had a significant effect on reducing the incidence of lung cancer and overall cancer mortality [95]. This evidence concerns the gene IL1B and cancer.